New FDA Pilot Program To Finger ‘Critical-To-Quality’ Points; First Up: Implantables With Batteries
This article was originally published in The Silver Sheet
Executive Summary
A “critical-to-quality” pilot program will launch early next year to help hone FDA investigators’ attention on manufacturing processes that are essential to the quality of implantable devices that include batteries. The agency, along with manufacturers and other stakeholders, will develop so-called “CTQs” that investigators will use to supplement FDA’s traditional QSIT inspectional approach. If the pilot goes well, FDA will likely develop a similar CTQ model for inspections of manufacturers that make devices other than implantables with batteries. Next for potential CTQS: cardiovascular products, IVDs, and general hospital and surgical devices?
You may also be interested in...
Device-Makers Can Forego US FDA Pre-Approval Inspections By Joining New 'Critical-To-Quality' PMA Pilot
Nine manufacturers will be selected to play in the agency's voluntary "Premarket Approval Application Critical to Quality" (PMA CtQ) pilot program. Participants will "discuss device design and manufacturing process quality information with FDA early on" to assist "in its review of the PMA manufacturing section and post-approval inspections," the agency says in a notice set to publish in the Sept. 12 Federal Register.
A Stronger Supply Chain: Stryker Tying Process Vendors To MedAccred; Others May Follow Suit As FDA Takes Notice
Suppliers of eight special manufacturing processes – including sterilization, welding and heat treating – will have to be accredited to industry-managed supply-chain oversight program MedAccred if they want to do future business with device giant Stryker. "Awarding business based on accreditation [to MedAccred] is the end goal," the company's manager of supplier controls told Medtech Insight. The program's aim is to ensure high-quality finished devices and offer clearer supply-chain visibility, giving manufacturers greater confidence in the vendors they choose. Industry heavy-hitters Medtronic, Johnson & Johnson, GE Healthcare, Philips Healthcare and Becton Dickinson are also strong supporters and users of MedAccred, giving it even more industry street cred. Meanwhile, resource-strapped US FDA is mulling over how it can best benefit from the burgeoning program.
FDA’s ISO Audit Program Chugs Along; May Be Absorbed By IMDRF Single-Audit Initiative
Thirty manufacturers have used FDA’s ISO 13485 voluntary audit program since the two-year pilot began last June, freeing up scarce agency inspectional resources to be used elsewhere. However, it will likely be eventually absorbed by a pilot Medical Device Single Audit Program currently under development by the International Medical Device Regulators Forum.